Replies to post #5183 on Halozyme Therapeutics Inc (HALO)

[maumar]

"Roche Holding AG’s breast cancer medicine Perjeta succeeded in the drugmaker’s most hotly anticipated patient study, a key step for a franchise that could exceed $9 billion in sales by 2021. The stock soared."

https://www.bloomberg.com/news/articles/2017-03-02/roche-s-perjeta-succeeds-with-key-aphinity-breast-cancer-study

[maumar]

I agree we are undervalued but I would think today's news must be part of the reason for today's move. Roche is up 6%.

"Some 70 percent of the drugmaker’s $6.8 billion in Herceptin revenue last year came from patients who might benefit from the combination tested in the trial, dubbed Affinity."

[Fred Kadiddlehopper]

Not too long ago, we had a $20 handle when biotech was in favor, then it wasn't and down we went. Now the wind is in biotech's sails again so any good news gets amplified instead of ignored. Near term $14.38 is major resistance.
Good luck
-Fritz